The clinical trials listed below are for informational purposes only and are not endorsed by the AST. More information on clinical trials can be found in our clinical trials brochure.
Clinical Trials - Recruiting
| Title | Sponsor | Organ Type | Ages Accepted | Expected Completion Date |
|---|---|---|---|---|
| An Open-Label, Multicenter, Phase 1B/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies [ARTACUS] | Replimune Inc. | All organs | 18+ | April 30, 2026 |
| Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) | Atara Biotherapeutics | All organs | All ages | June 30, 2027 |
| An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases (EBVision) | Atara Biotherapeutics | All organs | All ages | June 30, 2027 |
| Biogen | Kidney | 18-75 | Tuesday, June 1, 2027 | |
| Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant | Johns Hopkins School of Medicine | Kidney, Liver | 13-25 | June 1, 2026 |
Clinical Trials - Active, Not Recruiting
| Title | Sponsor | Organ Type | Ages Accepted | Expected Completion Date |
|---|---|---|---|---|
| Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) | AstraZeneca | All organs | January 21, 2025 | |
| Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (ConfIdeS) | Hansa Biopharma | Kidney | 18-70 | June 30, 2025 |
| BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation | Eledon Pharmaceuticals | Kidney | 18+ | March 31, 2025 |
Advertisements
This content was developed independently by AST and supported by a financial contribution from
